Cargando…
Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244808/ https://www.ncbi.nlm.nih.gov/pubmed/34965703 http://dx.doi.org/10.3324/haematol.2021.280284 |
| _version_ | 1784738605062684672 |
|---|---|
| author | Hamadani, Mehdi |
| author_facet | Hamadani, Mehdi |
| author_sort | Hamadani, Mehdi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9244808 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92448082022-07-07 Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? Hamadani, Mehdi Haematologica Editorials Fondazione Ferrata Storti 2022-07-01 /pmc/articles/PMC9244808/ /pubmed/34965703 http://dx.doi.org/10.3324/haematol.2021.280284 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Editorials Hamadani, Mehdi Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? |
| title | Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? |
| title_full | Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? |
| title_fullStr | Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? |
| title_full_unstemmed | Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? |
| title_short | Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? |
| title_sort | did brentuximab vedotin’s rise to the top echelon of hodgkin therapeutics invalidate aethera results? |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244808/ https://www.ncbi.nlm.nih.gov/pubmed/34965703 http://dx.doi.org/10.3324/haematol.2021.280284 |
| work_keys_str_mv | AT hamadanimehdi didbrentuximabvedotinsrisetothetopechelonofhodgkintherapeuticsinvalidateaetheraresults |